iTeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Down 21.1% in January

iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Free Report) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,500,000 shares, a decrease of 21.1% from the December 31st total of 1,900,000 shares. Approximately 4.9% of the company’s shares are sold short. Based on an average daily volume of 556,500 shares, the days-to-cover ratio is currently 2.7 days.

Insider Activity at iTeos Therapeutics

In related news, CFO Matthew Gall bought 5,000 shares of the stock in a transaction on Tuesday, November 19th. The stock was bought at an average price of $7.73 per share, with a total value of $38,650.00. Following the completion of the purchase, the chief financial officer now directly owns 65,429 shares in the company, valued at $505,766.17. This represents a 8.27 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 12.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On iTeos Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company lifted its holdings in iTeos Therapeutics by 6.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after purchasing an additional 690 shares in the last quarter. Creative Planning lifted its holdings in iTeos Therapeutics by 6.5% in the 3rd quarter. Creative Planning now owns 19,636 shares of the company’s stock valued at $200,000 after purchasing an additional 1,196 shares in the last quarter. SG Americas Securities LLC lifted its holdings in iTeos Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock valued at $106,000 after purchasing an additional 1,508 shares in the last quarter. nVerses Capital LLC lifted its holdings in iTeos Therapeutics by 212.5% in the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after purchasing an additional 1,700 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in iTeos Therapeutics by 60.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after purchasing an additional 2,646 shares in the last quarter. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS traded up $0.19 during trading on Thursday, hitting $7.68. 227,461 shares of the company were exchanged, compared to its average volume of 292,098. The company has a market cap of $280.55 million, a price-to-earnings ratio of -2.44 and a beta of 1.39. iTeos Therapeutics has a 1 year low of $7.09 and a 1 year high of $18.75. The firm’s fifty day moving average price is $7.87 and its 200 day moving average price is $11.10.

iTeos Therapeutics (NASDAQ:ITOSGet Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.18) by $0.13. On average, research analysts forecast that iTeos Therapeutics will post -3.49 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Friday, January 10th. Wells Fargo & Company reduced their target price on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of iTeos Therapeutics in a report on Thursday, January 16th.

View Our Latest Stock Report on ITOS

About iTeos Therapeutics

(Get Free Report)

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Featured Stories

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.